Free Trial

This company recently went public with an IPO on Wednesday, June 10th 2026. They issued 33,500,000 shares at $17.00 - $19.00 per share. We will continue to update data for PBLS as it becomes available.

Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026

$27.26 -3.05 (-10.06%)
As of 06/12/2026 04:00 PM Eastern

Latest Parabilis Medicines SEC Filings & Recent Activity

Parabilis Medicines (NASDAQ:PBLS) has submitted 37+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on June 11, 2026.

Form 4
Parabilis Medicines, Inc. Reports Ownership Change on Jun. 11, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

Parabilis Medicines SEC Filing History

Browse Parabilis Medicines' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
06/11/2026 7:07 PM
Deerfield Healthcare Innovations Fund, L.P. (1646981) Reporting
DEERFIELD MANAGEMENT COMPANY, L.P. (1009258) Reporting
Deerfield Mgmt HIF, L.P. (1665736) Reporting
Deerfield Mgmt III, L.P. (1610540) Reporting
Deerfield Private Design Fund III, L.P. (1603333) Reporting
Flynn James E (1352546) Reporting
Parabilis Medicines (1657677) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 5:36 PM
Kolchinsky Peter (1384859) Reporting
Parabilis Medicines (1657677) Issuer
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:52 PM
Parabilis Medicines (1657677) Issuer
Yeshwant Krishna (1585001) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:52 PM
Parabilis Medicines (1657677) Issuer
Weber Barbara (1800670) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:53 PM
Borisy Alexis (1319446) Reporting
Parabilis Medicines (1657677) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:41 PM
Parabilis Medicines (1657677) Issuer
SEBULSKY ALAN (1092348) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:43 PM
Klausner Richard (1591178) Reporting
Parabilis Medicines (1657677) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:47 PM
Parabilis Medicines (1657677) Issuer
Simson Jake (1863094) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:48 PM
FITZGERALD EDWARD M (1242993) Reporting
Parabilis Medicines (1657677) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2026 4:08 PM
Parabilis Medicines (1657677) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
06/10/2026 3:49 PM
Parabilis Medicines (1657677) Filer
Form 424B4
06/09/2026 7:38 PM
Parabilis Medicines (1657677) Subject
Form FWP
06/09/2026 11:15 PM
Parabilis Medicines (1657677) Filer
Form EFFECT
06/09/2026 8:30 PM
Kolchinsky Peter (1384859) Reporting
Parabilis Medicines (1657677) Issuer
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
Shah Rajeev M. (1619841) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:08 PM
Benzaghou Mohammed Fawzi (2135569) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:10 PM
FITZGERALD EDWARD M (1242993) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:11 PM
Ho Helen Huei-in (2135767) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:12 PM
Klausner Richard (1591178) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:13 PM
Jurgensen Teresa (2135568) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:15 PM
Deerfield Healthcare Innovations Fund, L.P. (1646981) Reporting
DEERFIELD MANAGEMENT COMPANY, L.P. (1009258) Reporting
Deerfield Mgmt HIF, L.P. (1665736) Reporting
Deerfield Mgmt III, L.P. (1610540) Reporting
Deerfield Private Design Fund III, L.P. (1603333) Reporting
Flynn James E (1352546) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:17 PM
Parabilis Medicines (1657677) Issuer
Yeshwant Krishna (1585001) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:17 PM
Mhatre Rohin (1798735) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:20 PM
Parabilis Medicines (1657677) Issuer
SEBULSKY ALAN (1092348) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:21 PM
Mammen Mathai (1421050) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:01 PM
Parabilis Medicines (1657677) Issuer
Weber Barbara (1800670) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:02 PM
Kotarakos Thomas Rodolpho (2135319) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:03 PM
Borisy Alexis (1319446) Reporting
Parabilis Medicines (1657677) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 8:06 PM
Parabilis Medicines (1657677) Issuer
Simson Jake (1863094) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/09/2026 5:46 PM
Parabilis Medicines (1657677) Filer
Form S-1MEF
06/09/2026 12:13 PM
Parabilis Medicines (1657677) Filer
Form CERT
06/09/2026 5:09 AM
Parabilis Medicines (1657677) Filer
Form S-1/A
06/04/2026 5:16 AM
Parabilis Medicines (1657677) Filer
Form S-1/A
05/27/2026 3:55 PM
Parabilis Medicines (1657677) Filer
Form S-1/A
(Data available from 1/1/2016 forward)

Parabilis Medicines SEC Filings - Frequently Asked Questions

Parabilis Medicines (PBLS) has submitted 37+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 4 submitted on June 11, 2026. This was an insider ownership change filed by 4 - Parabilis Medicines, Inc. (0001657677) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:PBLS) was last updated on 6/14/2026 by MarketBeat.com Staff.
From Our Partners